Toggle search
Toggle menu
406
21
32
6.1K
Pharmacopedia
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Drilldown: Medicines

More actions

Choose a table:


Medicines > generic: None & classes: D2/D3/5HT1A partial agonist & onset: Weeks for psychosis/mood efficacy

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
Vraylar (1)
classes: (Click arrow to add another value)
mechanism:
None (1)
uses:
Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1)
starting dose:
Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)
preparations:
1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1)
fda max:
6 mg/d (psychosis/mania); 3 mg/d (depression adjunct) (1)
routes:
Oral (1)
onset: (Click arrow to add another value)
duration:
Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) (1)
halflife:
Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1)
bioavailability:
Adequate oral bioavailability (1)
pregnancy:
Limited data (1)
legal:
Rx (1)

Showing below up to 1 result in range #1 to #1.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"